Cargando…
XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer
The epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) play critical roles in tumor growth, providing a strong rationale for the combined inhibition of IGF-1R and EGFR signaling in cancer therapy. We describe the design, affinity maturation, in vitro and i...
Autores principales: | Schanzer, Juergen M., Wartha, Katharina, Moessner, Ekkehard, Hosse, Ralf J., Moser, Samuel, Croasdale, Rebecca, Trochanowska, Halina, Shao, Cuiying, Wang, Peng, Shi, Lei, Weinzierl, Tina, Rieder, Natascha, Bacac, Marina, Ries, Carola H., Kettenberger, Hubert, Schlothauer, Tilman, Friess, Thomas, Umana, Pablo, Klein, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966845/ https://www.ncbi.nlm.nih.gov/pubmed/26984378 http://dx.doi.org/10.1080/19420862.2016.1160989 |
Ejemplares similares
-
Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing
por: Metz, Silke, et al.
Publicado: (2012) -
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
por: Bacac, Marina, et al.
Publicado: (2016) -
Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid
por: Eigenmann, Miro Julian, et al.
Publicado: (2021) -
End-to-end approach for the characterization and control of product-related impurities in T cell bispecific antibody preparations
por: Larivière, Laurent, et al.
Publicado: (2023) -
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
por: Scheuer, Werner, et al.
Publicado: (2016)